Skip to content

Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted to the Hospital.

Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted in the Hospital: a Multicenter Study (EME Study).

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02631226
Acronym
EME
Enrollment
580
Registered
2015-12-16
Start date
2016-02-29
Completion date
2017-12-31
Last updated
2016-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multi-resistant Enterobacteriaceae Colonisation, Nosocomial Outbreaks, Pregnancy

Brief summary

The purpose of this study is to determine the prevalence and risk factors for multi-resistant enterobacteriaceae colonization in less than 32 weeks pregnant women admitted to the hospital and its transmission to the newborn, in order to avoid neonatal intensive care unit spread and nosocomial outbreaks.

Interventions

None listed

Sponsors

Corporacion Parc Tauli
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

* Less than 32 weeks pregnant woman * Admitted to the hospital

Exclusion criteria

* Screening done after 48 hours of admission * When delivery occurs before screening is performed

Design outcomes

Primary

MeasureTime frame
Prevalence of multi-resistant enterobacteriaceae colonisation in less than 32 weeks pregnant women18 months

Secondary

MeasureTime frame
Prevalence of multi-resistant enterobacteriaceae colonisation of African or Asian pregnant women18 months
Incidence of multi-resistant enterobacteriaceae colonisation of pregnant women admitted to the hospital by preterm premature rupture of membranes (PPROM)18 months
Transmission rate from the colonized woman to the newborn18 months
Number of multi-resisitant enterobacteriacea sepsis in the Neonatal Unit18 months

Countries

Spain

Contacts

Primary ContactVictoria Aldecoa-Bilbao, M.D.
valdecoa@tauli.cat0034937231010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026